The Potential for Targeting the STAT3 Pathway as a Novel Therapy for Melanoma
2013; Future Medicine; Volume: 9; Issue: 7 Linguagem: Inglês
10.2217/fon.13.83
ISSN1744-8301
Autores Tópico(s)Cancer Mechanisms and Therapy
ResumoFuture OncologyVol. 9, No. 7 EditorialThe potential for targeting the STAT3 pathway as a novel therapy for melanomaGregory B LesinskiGregory B LesinskiThe Ohio State University, Arthur G James Cancer Hospital & Richard J Solove Research Institute, Department of Internal Medicine, Division of Medical Oncology, The Ohio State University, 400 West 12th Avenue, Columbus, OH 43210, USA. Published Online:3 Jul 2013https://doi.org/10.2217/fon.13.83AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: cytokineimmunotherapyJak/STATJak2melanomaSTAT3References1 Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med.363(9),809–819 (2010).Crossref, Medline, CAS, Google Scholar2 Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J. Clin.62(5),309–335 (2012).Crossref, Medline, Google Scholar3 Kortylewski M, Jove R, Yu H. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev.24(2),315–327 (2005).Crossref, Medline, CAS, Google Scholar4 Niu G, Bowman T, Huang M et al. Roles of activated Src and STAT3 signaling in melanoma tumor cell growth. Oncogene21(46),7001–7010 (2002).Crossref, Medline, CAS, Google Scholar5 Xie TX, Huang FJ, Aldape KD et al. Activation of STAT3 in human melanoma promotes brain metastasis. Cancer Res.66(6),3188–3196 (2006).Crossref, Medline, CAS, Google Scholar6 Akira S. Roles of STAT3 defined by tissue-specific gene targeting. Oncogene19(21),2607–2611 (2000).Crossref, Medline, CAS, Google Scholar7 Takeda K, Noguchi K, Shi W et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl Acad. Sci. USA94(8),3801–3804 (1997).Crossref, Medline, CAS, Google Scholar8 Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer9(11),798–809 (2009).Crossref, Medline, CAS, Google Scholar9 Zhang X, Yue P, Page BD et al. Orally bioavailable small-molecule inhibitor of transcription factor STAT3 regresses human breast and lung cancer xenografts. Proc. Natl Acad. Sci. USA109(24),9623–9628 (2012).Crossref, Medline, CAS, Google Scholar10 Yue P, Turkson J. Targeting STAT3 in cancer: how successful are we? Expert Opin. Investig. Drugs18(1),45–56 (2009).Crossref, Medline, CAS, Google Scholar11 Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of STAT3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res.69(6),2506–2513 (2009).Crossref, Medline, CAS, Google Scholar12 Kong LY, Gelbard A, Wei J et al. Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model. Clin. Cancer Res.16(9),2550–2561 (2010).Crossref, Medline, CAS, Google Scholar13 Kortylewski M, Swiderski P, Herrmann A et al.In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat. Biotechnol.27(10),925–932 (2009).Crossref, Medline, CAS, Google Scholar14 Kujawski M, Zhang C, Herrmann A et al. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res.70(23),9599–9610 (2010).Crossref, Medline, CAS, Google Scholar15 Bill MA, Fuchs JR, Li C et al. The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. Mol. Cancer9,165 (2010).Crossref, Medline, Google Scholar16 Bill MA, Nicholas C, Mace TA et al. Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines. PLoS ONE7(8),e40724 (2012).Crossref, Medline, CAS, Google Scholar17 Liu F, Cao J, Wu J et al. STAT3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas. J. Invest.Dermatol. doi:10.1038/jid.2013.32 (2013) (Epub ahead of print).Google Scholar18 Becker TM, Boyd SC, Mijatov B et al. Mutant B–RAF–Mcl-1 survival signaling depends on the STAT3 transcription factor. Oncogene doi:10.1038/onc.2013.45 (2013) (Epub ahead of print).Medline, Google Scholar19 Girotti MR, Pedersen M, Sanchez-Laorden B et al. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov.3(2),158–167 (2013).Crossref, Medline, CAS, Google Scholar20 Quintás-Cardama A, Verstovsek S. Molecular Pathways: JAK/STAT pathway: mutations, inhibitors, and resistance. Clin. Cancer Res.19(8),1933–1940 (2013).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByIn vitro and in silico study on the effect of carvedilol and sorafenib alone and in combination on the growth and inflammatory response of melanoma cellsSaudi Pharmaceutical Journal, Vol. 31, No. 7The role of dual‐specificity phosphatase 3 in melanocytic oncogenesis7 August 2022 | Experimental Dermatology, Vol. 31, No. 10Luteolin binds Src, promotes STAT3 protein ubiquitination and exerts anti-melanoma effects in cell and mouse modelsBiochemical Pharmacology, Vol. 200Interleukin-8 in Melanoma Pathogenesis, Prognosis and Therapy—An Integrated View into Other Neoplasms and Chemokine Networks30 December 2021 | Cells, Vol. 11, No. 1Amygdalin promotes the activity of T cells to suppress the progression of HBV-related hepatocellular carcinoma via the JAK2/STAT3 signaling pathway12 January 2021 | BMC Infectious Diseases, Vol. 21, No. 1Mambalgin-2 Inhibits Growth, Migration, and Invasion of Metastatic Melanoma Cells by Targeting the Channels Containing an ASIC1a Subunit Whose Up-Regulation Correlates with Poor Survival Prognosis26 September 2021 | Biomedicines, Vol. 9, No. 10A two-herb formula inhibits STAT3 signaling and exerts anti-melanoma effects in cell and animal modelsJournal of Ethnopharmacology, Vol. 268Emerging impact of the long noncoding RNA MIR22HG on proliferation and apoptosis in multiple human cancers3 December 2020 | Journal of Experimental & Clinical Cancer Research, Vol. 39, No. 1Melanoma en el síndrome de Noonan con lentigos múltiples (síndrome de LEOPARD): presentación de un nuevo casoActas Dermo-Sifiliográficas, Vol. 111, No. 7Melanoma in Noonan Syndrome With Multiple Lentigines (LEOPARD syndrome): A new caseActas Dermo-Sifiliográficas (English Edition), Vol. 111, No. 7COL2A1 Is a Novel Biomarker of Melanoma Tumor Repopulating Cells18 September 2020 | Biomedicines, Vol. 8, No. 9Cytotoxic Activities and Molecular Mechanisms of the Beauvericin and Beauvericin G1 Microbial Products against Melanoma Cells23 April 2020 | Molecules, Vol. 25, No. 8Low dose radiation regulates BRAF-induced thyroid cellular dysfunction and transformation13 February 2019 | Cell Communication and Signaling, Vol. 17, No. 1STAT3 and STAT5 Targeting for Simultaneous Management of Melanoma and Autoimmune Diseases27 September 2019 | Cancers, Vol. 11, No. 10Macrophages in skin melanoma-the key element in melanomagenesis (Review)9 February 2018 | Oncology LettersPatient with confirmed leopard syndrome developing multiple myeloma31 January 2018 | Dermatology Practical & ConceptualInhibition of Jak/STAT signaling reduces the activation of pancreatic stellate cells in vitro and limits caerulein-induced chronic pancreatitis in vivo11 May 2017 | Scientific Reports, Vol. 7, No. 1STAT3 activation in infection and infection-associated cancerMolecular and Cellular Endocrinology, Vol. 451Renalase Expression by Melanoma and Tumor-Associated Macrophages Promotes Tumor Growth through a STAT3-Mediated Mechanism30 June 2016 | Cancer Research, Vol. 76, No. 13Mécanismes de résistance aux inhibiteurs de BRAFAnnales de Dermatologie et de Vénéréologie, Vol. 141, No. 11Aberrant expression of p-STAT3 in peripheral blood CD4+ and CD8+ T cells related to hepatocellular carcinoma development21 August 2014 | Molecular Medicine Reports, Vol. 10, No. 5Dendritic cells with an increased PD-L1 by TGF-β induce T cell anergy for the cytotoxicity of hepatocellular carcinoma cellsInternational Immunopharmacology, Vol. 20, No. 1 Vol. 9, No. 7 STAY CONNECTED Metrics Downloaded 121 times History Published online 3 July 2013 Published in print July 2013 Information© Future Medicine LtdKeywordscytokineimmunotherapyJak/STATJak2melanomaSTAT3AcknowlegementsThe author would like to thank the numerous collaborators who have contributed to knowledge in the area of targeting the Jak/STAT pathway in melanoma. The author also apologizes to all his colleagues whose important work could not be directly cited.Financial & competing interests disclosureGB Lesinski receives research funding from Prometheus, Inc., Karyopharm Therapeutics, Inc., Oncolytics, Inc., Array Biopharma, Inc. and Bristol Myers-Squibb, Inc. GB Lesinski receives salary and research support from the following NIH grant: 1R21 CA173473-01. GB Lesinski serves as a consultant for Ono Pharmaceuticals, Inc. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download
Referência(s)